Cryoport Systems Expands Global Footprint with New Global Supply Chain Center in Paris, France
Cryoport (NASDAQ: CYRX) has announced the opening of a new 55,000-square-foot Global Supply Chain Center (GSCC) in Louvres, France, near Paris Charles de Gaulle Airport. The facility represents the company's third global supply chain center campus, strengthening its temperature-controlled supply chain solutions network.
The Paris GSCC will provide 24-hour worldwide dispatch capabilities and immediate logistics support for biopharma, including cell and gene therapies, biologics, animal health, and reproductive medicine. Future phases will incorporate BioServices, biostorage, QP drug management, and Importer of Record services. The facility's development was partially funded by a grant from the Île-de-France region, with an official grand opening scheduled for November 20, 2025.
- Strategic location near Paris Charles de Gaulle Airport enhances global accessibility
- Expansion of end-to-end temperature-controlled supply chain capabilities in Europe
- Partial funding secured through regional grant from Île-de-France
- 24-hour worldwide dispatch capabilities from order receipt
- Phased implementation means full service offerings won't be immediately available
Insights
Cryoport's new Paris facility strategically expands their European biologistics network, enhancing operational capabilities and market competitiveness.
Cryoport's new 55,000-square-foot Global Supply Chain Center near Paris Charles de Gaulle Airport represents a calculated strategic expansion of their temperature-controlled logistics infrastructure. The facility's proximity to a major international hub maximizes distribution efficiency for time-sensitive and temperature-critical biological materials across European markets.
The phased implementation approach is particularly noteworthy. Beginning with core logistics services and progressively adding more complex offerings like QP drug management and Importer of Record services demonstrates operational discipline. This methodical rollout minimizes execution risk while ensuring service quality standards are maintained throughout the expansion.
Securing partial funding through a regional grant from Île-de-France indicates government recognition of the facility's economic development value and positions Cryoport advantageously from a capital efficiency perspective. This public-private partnership model reduces capital expenditure burden while accelerating operational readiness.
The Paris facility, as Cryoport's third global supply chain center, creates a more robust network effect across their service platform. With 24-hour worldwide dispatch capabilities, the company strengthens its competitive position in supporting advanced therapy logistics, particularly for cell and gene therapies where temperature control integrity is absolutely critical to therapeutic efficacy.
This expansion directly addresses the complex cold-chain requirements facing biopharmaceutical developers as more temperature-sensitive advanced therapies progress through clinical trials toward commercialization. By integrating biostorage and logistics under one roof, Cryoport is positioning itself as an end-to-end solution provider in a specialized market segment with significant barriers to entry.
The 55,000-Square-Foot Facility is the Latest Addition to Cryoport Systems' Global Supply Chain Center Network
Designed to Support Complex Life Sciences Supply Chain Needs, Including Biologistics, BioServices and Future Cryopreservation Services Worldwide
Purpose-built to streamline operations and address critical challenges in the advanced therapies market, the facility provides end-to-end, temperature-controlled supply chain solutions under one roof. As the third global supply chain center campus in Cryoport's network, it will offer global accessibility for biopharma and other temperature-sensitive commodities.
The facility will be immediately operational, providing logistics support for biopharma, including cell and gene therapies, biologics, animal health and reproductive medicine. During the months following, the Paris GSCC will add BioServices, biostorage, QP drug management, Importer of Record (IOR) services and additional offerings from Cryoport Systems' suite of services. This phased, integrated approach will support both clinical and commercial cell and gene therapy programs.
"Our new facility in Louvres strengthens Cryoport Systems' Global Supply Chain Center Network significantly and provides us with increased ability to serve our clients in the European and global markets," said Jerrell Shelton, CEO of Cryoport. "By providing integrated capabilities and end-to-end services, we will continue to ensure secure, compliant handling of temperature-sensitive commodities and help our clients to deliver therapies safely and efficiently to patients in need."
With today's launch of logistical operations, the facility will offer 24-hour worldwide dispatch capabilities from order receipt to deployment of Cryoport's wholly owned fleet of proprietary shipping systems. It will also offer the same demanding quality oversight in full alignment with Cryoport Systems' GSCC network. The Paris GSCC was funded, in part, by a grant provided to Cryoport Systems by the Île-de-
An official grand opening to celebrate the launch of the Paris GSCC will be held on November 20, 2025, bringing together local dignitaries, distinguished members of Île-de-
About Cryoport, Inc.
Cryoport, Inc.
(Nasdaq: CYRX), is a leading global provider of temperature-controlled supply chain solutions for the Life Sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the Life Sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are "Enabling the Future of Medicine™."
Headquartered in
For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.twitter.com/cryoport for live updates.
Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-systems-expands-global-footprint-with-new-global-supply-chain-center-in-paris-france-302571873.html
SOURCE Cryoport, Inc.
FAQ
What is the size and location of Cryoport's new facility in France?
What services will CYRX's new Paris facility provide?
When will Cryoport's Paris Global Supply Chain Center be fully operational?
How many global supply chain centers does Cryoport now operate?
When is the official grand opening of Cryoport's Paris facility?
